Company Overview and News
Reuters – Sri Lankan shares fell on Friday from a near two-week high hit in the previous session as investors waited for cues from the national budget scheduled on Nov. 10.
LONDON, Sept. 22, 2016 /PRNewswire/ -- This report analyzes the worldwide markets for Hot Beverages (Coffee and Tea) in US$ Million and Thousand Tons by the following Product Segments: Coffee, and Tea. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.
Close to 40 of the most elite brands in Sri Lanka will be displaying the best of local products at a special exhibition that will coincide with the World Export Development Forum (WEDF) 2016. With the global summit scheduled to be held in Sri Lanka on the 12th and 13th of October this year, Sri Lankan enterprises such as Brandix Apparel Ltd, MAS Holdings, Akbar Brothers, Ceylon Tea Services, Camso Loadstar, Virtusa, 99X Technology, Gem Paradise and H.
NEW YORK, June 23, 2016 /PRNewswire/ -- This report analyzes the worldwide markets for Hot Beverages (Coffee and Tea) in US$ Million and Thousand Tons by the following Product Segments: Coffee, and Tea. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.
Ceylon Biscuits Limited and Holcim Lanka partners to co-finance Sri Lanka’s first National Summit on Foresight and Innovation for Sustainable Human Development. The Summit organized by the United Nations Development Programme (UNDP) and the Ministry of National Policies and Economic Affairs together with many core partners including the United Nations Global Compact Network Ceylon (UNGC) and the Ceylon Chamber of Commerce (CCC), will take place on the 24th -25th of May at Waters Edge, Battaramulla.
20h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
21h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...